ArticlePeerJ2026
Chinese thyroid imaging reporting and data system with redefined marked hypoechogenicity for thyroid malignancy risk stratification demonstrates improved diagnostic accuracy.
Article in PeerJ, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Using ultrasound to distinguish between benign and malignant thyroid nodules can be challenging. The purpose of this study was to evaluate the diagnostic performance of a modified Chinese Thyroid Imaging Reporting and Data System (C-TIRADS) that incorporates a redefined criterion for marked hypoechogenicity in stratifying the malignancy risk of thyroid nodules. Methods: In this retrospective study, we analyzed patients with thyroid nodules who underwent ultrasound examination and subsequent biopsy or treatment at a tertiary hospital between January 2022 and December 2023. Interobserver agreement in identifying marked hypoechogenicity between two reviewers was assessed using kappa statistics. Using histopathology as the reference standard, the diagnostic performance of three classification systems, including the classical C-TIRADS, the modified C-TIRADS, and the 2021 K-TIRADS, was compared in terms of sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), accuracy, and the area under the receiver operating characteristic curve (AUC). Results: The study included 1,219 patients with 1,721 thyroid nodules. After redefining marked hypoechogenicity, interobserver agreement (kappa) improved from 0.652 to 0.722. Compared to the original criterion, the redefined marked hypoechogenicity demonstrated significantly higher sensitivity (74.5% Conclusion: The modified C-TIRADS, incorporating a redefined criterion of marked hypoechogenicity, shows improved diagnostic performance in stratifying the malignancy risk of thyroid nodules and provides risk assessments that align more closely with the expected probabilities outlined in the (classical) C-TIRADS guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.